This research has helped in the development of new diagnostic tests and new treatments, e.g. the presence of HER2 to determine which patients are likely to derive benefit from trastuzumab and the development of tamoxifen for the treatment of breast cancer (Gottardis et al. 1988; Slamon et al. 1989). This evidence concerns the gene ERBB2 and breast carcinoma.